Navigation Links
BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
Date:6/9/2008

PLYMOUTH MEETING, Pa., June 9 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that Zhiqiang Han, currently President of BMP Sunstone Corporation and a member of the Board of Directors, has been appointed to President and Chief Operating Officer of BMP Sunstone Corporation, effective immediately.

Mr. Han has served as President of BMP Sunstone since April 2008 and played an integral role in the acquisition of Sunstone (Tangshan) Pharmaceutical Corporation, Ltd., which he founded in 1996. Prior to founding Sunstone Corporation, Mr. Han was Managing Director of Tangshan Changrong Pharmaceuticals and Chief Engineer of Logistics and Assistant to the Plant Director with Tangshan Women and Children's Pharmaceutical Manufacturer. Mr. Han has also served as Vice President of the China Nonprescription Medicine Association; Chairman of Hebei Industry and Economic Union; and Vice President of the Hebei Pharmaceutical Industry Association. Mr. Han earned a Bachelor of Science degree from Shenyang Pharmaceutical University and a Masters in Business Administration degree from Dalian University of Technology.

Mr. David Gao, Chief Executive Officer of BMP Sunstone said, "Mr. Han's strong leadership capabilities, combined with his proven operating skills and deep understanding of China's pharmaceutical industry, make him a great fit for the role of Chief Operating Officer. I look forward to working with him side by side to optimize BMP Sunstone's cost structure, drive productivity and profitability, and generally maximize the synergies between our various business units over time."

Mr. Han commented, "I am confident in my shared vision and goals with David, and intend to immediately focus on driving growth and operating efficiencies at Sunstone as well as across our entire BMP Sunstone platform."

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The Company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio primarily focuses on women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Pennsylvania.

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about optimizing BMP Sunstone's cost structure, improving productivity and profitability, and maximizing the synergies between the Companies business units. These statements are subject to uncertainties and risks including, but not limited to, our ability to generate additional revenue, control our expenses and take advantage of synergies between our various subsidiaries and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BMP Sunstone Receives Import Drug License (IDL) from SFDA
2. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
3. DURECT Corporation to Participate in Upcoming Healthcare Conferences
4. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
5. Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.
6. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
7. David M. Stout Joins NanoBio Corporations Board of Directors
8. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
9. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
10. Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine
11. Immunosyn Corporation Files 10-Q
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... published evaluation of multiple immunoassay-based threat detection technologies by researchers from the ... CANARY® biosensor threat detection technology was found to have the best level ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The Greater ... a new partnership with Compass Research . GGI's mission is to advance global ... to a child in need in honor of each clinical trial volunteer. The vision ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
Breaking Biology News(10 mins):